Advertisement

Interférences avec la cascade immuno-inflammatoire

  • I. Boyadjiev
  • F. Garnier
  • C. Martin
Part of the Le point sur⋯ book series (POINT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Bone RC (1991) Sepsis, the sepsis syndrome, multiple organ failure: a pleace for comparable definitions. Ann Intern Med 114: 332–3PubMedGoogle Scholar
  2. 2.
    Centers for Disease Control (1990) Increase in national hospital discharge survey rates for septicemia. Morbidity and Mortality Weekly Report 39: 31–4Google Scholar
  3. 3.
    Ziegler EJ, Mc Cutchan JA, Fierer J et al. (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307: 1225-30Google Scholar
  4. 4.
    Ziegler EJ, Fisher CJ, Sprung CL et al. (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 324: 429–36PubMedGoogle Scholar
  5. 5.
    Sprung CL, Caralis PV, Martial EH et al. (1984) The effects of high dose corticosteroids in patients with septic shock. N Engl J Med 311: 1137–43PubMedGoogle Scholar
  6. 6.
    Kaufman BS, Rackow EC, Falk JL (1984) The relationship between oxygen delivery and consumption during fluid resuscitation of hypovolemic and septic shock. Chest 85: 336–40PubMedGoogle Scholar
  7. 7.
    Nasraway SA (2003) The problems and challenges of immunotherapy in sepsis. Chest 123: 4515–95CrossRefGoogle Scholar
  8. 8.
    Michie HR, Manogue KR, Spriggs DR et al. (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318: 1481–6PubMedGoogle Scholar
  9. 9.
    Baumgartner JD, Glauser MP (1987) Controversies in the use of passive immunotherapy for bacterial infections in the critically ill patient. Rev Infect Dis 9: 194–205PubMedGoogle Scholar
  10. 10.
    Zinner SH, Mc Cabe WR (1976) Effects of IgM and IgG antibody in patients with bacteremia due to Gram-negative bacilli. J Infect Dis 133: 37–45PubMedGoogle Scholar
  11. 11.
    Lachman E, Pitsoe SB, Gaffin SL (1984) Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetrical and gynaecological origin. Lancet 1: 981–3PubMedGoogle Scholar
  12. 12.
    Fomsgaard A, Back L, Fomsgaard JS, Engquist A (1989) Preliminary study on treatment of septic shock patients with antilipopolysaccharide IgG from blood donors. Scand. J Infect Dis 21: 697–708Google Scholar
  13. 13.
    Schedel I, Dreikhaussen U, Neutwig B et al. (1991) Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 19: 1104–13PubMedGoogle Scholar
  14. 14.
    Baumgartner JD, Glauser PG, Mc Cutchan JA et al. (1985) Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 2: 59–63PubMedGoogle Scholar
  15. 15.
    Calandra T, Glauser MP, Schellekens J, Verhoef J, the Swiss-Dutch J5 Immunoglobulin Study Group (1988) Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli: a prospective, double-blind, randomized trial. J Infect Dis 158: 312–9PubMedGoogle Scholar
  16. 16.
    J5 Study Group (1992) Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double blind study. J Infect Dis 165: 695–701Google Scholar
  17. 17.
    Mc Cutchan JA, Wolf JL, Ziegler EJ, Brande AI (1988) Ineffectiveness of single-dose human antiserum to core glycolipid (Escherichia coli J5) for prophylaxis of bacteremic, Gram-negative infection in patients with prolonged neutropenia. Schw Mediz Woch 113,suppl. 40–5Google Scholar
  18. 18.
    The Intravenous Immunoglobulin Collaborative Study Group (1992) Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysacchardic immune globulin in patients at risk of postsurgical infection. N Engl J Med 327: 234–40Google Scholar
  19. 19.
    Calandra T, Baumgartner JD, 1995: Anti-endotoxin therapy. In Critical trials for the treatment of sepsis Update in Intensive Care and Emergency Medicine, 19. WJ. Sibbald and JL, Vincent (eds) Springer-Verlag, Berlin, 1 vol., 406 p. (pp. 237–50)Google Scholar
  20. 20.
    Baumgartner JD, Heumann D, Glauser MP (1991) The HA-1A monoclonal antibody for Gram-negative sepsis. N Engl J Med (Letter) 325: 281–2Google Scholar
  21. 21.
    Luce JM (1993) Introduction of newtechnology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Crit Care Med 21: 1233–41PubMedGoogle Scholar
  22. 22.
    Siegel JP, Stein KE, Zoon KC (1992) Anti-endotoxin monoclonal antibodies (the FDA reply). N Engl J Med 327: 890–1Google Scholar
  23. 23.
    Wenzel RP (1992) Anti-endotoxin monoclonal antibodies. A second look. N Engl J Med 326: 1151–13PubMedGoogle Scholar
  24. 24.
    Wenzel RP, Andriole T, Bartlett JG (1992) Antiendotoxin monoclonal antibodies for gramnegative sepsis: guidelines from the Infectious Disease Society of America. Clin Infect Dis 14: 973–6PubMedGoogle Scholar
  25. 25.
    Ziegler EJ, Smith CR (1992) Anti-endotoxin monoclonal antibodies. N Engl J Med (Letter) 326: 1165PubMedGoogle Scholar
  26. 26.
    Mc Closkey RV, Straube RC, Sanders C, Smith CR and the CHESS Trial Study Group (1994) Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial period. Ann Intern Med 121: 1–5Google Scholar
  27. 27.
    Anonyme (1994) The french national registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. Arch Intern Med 154: 2484–91Google Scholar
  28. 28.
    Kett DH, Quartin AA, Sprung CL et al. (1994) An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody. Crit Care Med 22: 1227–34PubMedGoogle Scholar
  29. 29.
    Greenmam RL, Schein RMH, Martin MA et al. (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 266: 1097–102Google Scholar
  30. 30.
    Bone RC, Balk RA, Fein AM et al. (1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 23: 994–1006PubMedGoogle Scholar
  31. 31.
    Wenzel R, Bone RC, Feui A et al. (1991) Results of a second double-blind randomized controlled trial of antiendotoxin antibody E5 in gram-negative sepsis 31st ICAAC Chicago no 1170, p 294Google Scholar
  32. 32.
    Greenberg RN, Wilson KM, Kunz AY et al. (1992) Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected serious gram-negative sepsis. Crit Care Med. 20: 730–5PubMedGoogle Scholar
  33. 33.
    Albertson TE, Panacek EA, MacArthur RD et al. (2003) Multicenter evaluation of human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit Care Med 31: 419–27PubMedGoogle Scholar
  34. 34.
    Morrison DC, Silverstein R, Parmely MJ (1992) Novel approaches to the treatment of septic shock in Yearbook of Intensive Care and Emergency Medicine, JL Vincent Editor, Springer Verlag, Berlin, 1 vol. (pp 91–103)Google Scholar
  35. 35.
    Proctor RA, Will JA, Burhop KE, Raetz CRH (1986) Protection of mice against lethal endotoxemia by a lipid A precursor. Infect Immun 52: 905–7PubMedGoogle Scholar
  36. 36.
    Fisher CJ Jr, Marra MN, Palardy JE (1994) Human neutrophil bactericidal/permeabilityincreasing protein reduces mortality rate from endotoxin challenge. A placebo-controlled study. Crit Care Med 22: 553–8PubMedGoogle Scholar
  37. 37.
    Levin M, Quint PA, Goldstein B et al. (2000) Recombinant bactericidal/permeability increasing protein as adjunctive treatment for children with severe meningoccal sepsis: A randomized trial. Lancet 356: 961–7PubMedGoogle Scholar
  38. 38.
    Hesse DG, Tracey KJ, Fong Y et al. (1988) Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 166: 147–53PubMedGoogle Scholar
  39. 39.
    Tracey KJ, Vlasara H, Cerami A (1989) Cachectin/tumor necrosis factor. Lancet 1: 1122–6PubMedGoogle Scholar
  40. 40.
    Beutler B, Cerami A (1986) Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320: 584–8CrossRefPubMedGoogle Scholar
  41. 41.
    Beutler B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316: 379–85PubMedGoogle Scholar
  42. 42.
    Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869–71PubMedGoogle Scholar
  43. 43.
    Tracey KJ, Beutler B, Lowry SF et al. (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234: 470–3PubMedGoogle Scholar
  44. 44.
    Mathison JC, Wolfson E, Ulevitch RJ (1988) Participation of tumor necrosis factor in the mediation of Gram-negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 81: 1925–37PubMedGoogle Scholar
  45. 45.
    Silva AT, Bayston KF, Cohen J (1990) Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-α in experimental gram-negative shock. J Infect Dis 162: 421–27PubMedGoogle Scholar
  46. 46.
    Tracey KJ, Fong Y, Hesse DG et al. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330: 662–4CrossRefPubMedGoogle Scholar
  47. 47.
    Hinshaw LB, Tekamp-Olson P, Chang ACK et al. (1990) Survival of primates in LD 100 septic shock following therapy with antibody to tumor necrosis factor (TNFα). Cir Shock 30: 279–92Google Scholar
  48. 48.
    Opal SM, Cross AS, Kelly NM et al. (1990) Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis 161: 1148–52PubMedGoogle Scholar
  49. 49.
    Duerr ML, Valdenz CM, Emersonte Hinshaw LB, Fournel MA (1991) Serum kinetics of cytokine after TNFα monoclonal antibody (mab.) treatment in gram negative and positive bacteremic baboon models. 31st ICAAC Chicago, no 538Google Scholar
  50. 50.
    Wayne J, Silva A, Cohen J (1991) Role of tumor necrosis factor (TNF) in experimental gram positive sepsis. 31st ICAAC Chicago, no 789Google Scholar
  51. 51.
    Bagdy GJ, Plessala KJ, Wilson LA et al. (1991) Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of septic shock. J Infect Dis 163: 83–8Google Scholar
  52. 52.
    Zanetti G, Kohler J, Heumann D et al. (1991) Failure of anti-TNF mAb in preventing death in peritonitis-induced Gram-negative bacteremia in mice. 31st ICAAC Chicago p 294, no 790.Google Scholar
  53. 53.
    Collins MS, Mehton NS, Hector RF et al. (1991) Treatment of acute peritonitis in young swine with gentamicin and a monoclonal antibody against tumor necrosis factor α. 31st ICAAC Chicago, no 540Google Scholar
  54. 54.
    Opal SM, Cross AS, Sadoff JC et al. (1991) Efficacy of antilipopoly saccharide and antitumor necrosis factor monoclonal antibodies in a neutropenic model of Pseudomonas sepsis. J Clin Invest 88: 885–90PubMedGoogle Scholar
  55. 55.
    Franks AK, Kujawa KI, Yaffe LJ (1991) Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival. Infect Immun 59: 2609–14PubMedGoogle Scholar
  56. 56.
    Silva AT, Appelmelk BJ, Baurman WA, Bayston KF, Cohen J (1990) Monoclonal antibody to endotoxin core protects mice from Escherichia coli sepsis by a mechanism independent of tumor necrosis factor and interleukine 6. J Infect Dis 162: 454–9PubMedGoogle Scholar
  57. 57.
    Exley AR, Cohen J, Buurman W et al. (1990) Monoclonal antibody to TNF in severe septic shock. Lancet 2: 1275–7Google Scholar
  58. 58.
    Fisher CJ Jr, Opal SM, Dhainaut JF et al. (1994) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 21: 318–27Google Scholar
  59. 59.
    Dhainaut JF, Vincent JL, Richard C et al. (1995) CDP 571, a humanized antibody to human tumor necrosis factor-α: safety, pharmacokinetics, immune response, and influence ot the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 23: 1461–9PubMedGoogle Scholar
  60. 60.
    Zimmerman JL, Dillon K, Campbell W, Reinhart K (1994): Phase I/II trial of cA2, a chimeric anti TNF antibody in patients with sepsis. Intensive Care Med 20, S151Google Scholar
  61. 61.
    Reinhart K, Wiegand-Lohnert C, Grimminger F et al. (1998) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, doseranging study. Crit Care Med 24: 733–42Google Scholar
  62. 62.
    Reinhart K, Menges T, Gardlund B et al. (2001) Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES Study. Crit Care Med 29: 765–9PubMedGoogle Scholar
  63. 63.
    Abraham E, Wunderink R, Silverman H et al. (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor ? in patients with sepsis syndrome. JAMA 273: 934–41CrossRefPubMedGoogle Scholar
  64. 64.
    Abraham E, Anzueto A, Guitierrez G et al. (1998) Monoclonal antibody to human tumor necrosis factor alpha (TNF Mab) in the treatment of patients with septic shock: a multicenter, placebo-controlled, randomized, double-blind clinical trial. Lancet 351: 929–33PubMedGoogle Scholar
  65. 65.
    Cohen J, Carlet J (1996) INTERSEPT: an international multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 24: 1431–440PubMedGoogle Scholar
  66. 66.
    Fisher CJ Jr, Agosti JM, Opal SM et al. (1996) Treatment of septic shock with the tumor necrosis factor receptor Fc fusion protein. N Engl J Med 334: 1697–1702PubMedGoogle Scholar
  67. 67.
    Abraham E, Glauser MP, Buther T et al. (1997) p 55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA 277: 1531–4CrossRefPubMedGoogle Scholar
  68. 68.
    Abraham E, Laterre PF, Garbino J et al. (2001) Lenercept (p 55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebocontrolled, multicenter phase III trial with 1 342 patients. Crit Care Med 29: 503–10PubMedGoogle Scholar
  69. 69.
    Marshall JC (2003) Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nature Rev 2: 391–405Google Scholar
  70. 70.
    Seckinger P, Lowenthal JW, Williamson K et al. (1987): A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol 139: 1546–9PubMedGoogle Scholar
  71. 71.
    Fisher CJ Jr, Slotman GJ, Opal SM et al. (1994) Initial evaluation of human recombinant interleukin-1 receptor antognosit in the treatment of sepsis syndrome: a randomized, openlabel, placebo-controlled mutlicenter study. Crit Care Med 22: 12–21PubMedGoogle Scholar
  72. 72.
    Fisher JC Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman TJ et al. (1994): Recombinant human interleukin-1 receptor antagonist in the treatment of patients with the sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 271: 1836–43CrossRefPubMedGoogle Scholar
  73. 73.
    Opal SM, Fischer CJ, Pribble JP et al. (1997) The confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25: 1115–24PubMedGoogle Scholar
  74. 74.
    Redmond HP, Chavin KD, Bromberg JS, Daly JM (1991): Inhibition of macrophage-activating cytokines is beneficial in the acute septic response. Ann Surg 214: 502–9PubMedGoogle Scholar
  75. 75.
    Döcke WD, Randow F, Syrbe U et al. (1997) Monocyte deactivation in septic patients: restoration by INF-α treatment Nat Med 3: 678–81PubMedGoogle Scholar
  76. 76.
    Presneill JJ, Harris T, Stewart AG et al. (2002) A randomized Phase II trial of granulocytemacrophage colony-stimulating factor in therapy of severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 166: 138–43CrossRefPubMedGoogle Scholar
  77. 77.
    Dhainaut JF, Tenaillon A, le Tulzo Y et al. (1994) Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22: 1720–8PubMedGoogle Scholar
  78. 78.
    Dhainaut JF, Tenaillon A, Hemmer M et al. (1998) Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 26: 1963–71PubMedGoogle Scholar
  79. 79.
    Vincent JL, Spapon H, Bakker J et al. (2000) Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med 28: 638–42PubMedGoogle Scholar
  80. 80.
    Poeze M, Froon AH, Ramsay G et al. (2002) Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309. Shock 14: 421–8Google Scholar
  81. 81.
    Froon AM, Greve JW, Buurman WA et al. (1996) Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome. Shock 5: 313–9PubMedGoogle Scholar
  82. 82.
    Suputtamongkol Y, Intaranongpai S, Smith MD et al. (2000) A double-blind placebocontrolled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrob Agents Chemother 44: 693–6CrossRefPubMedGoogle Scholar
  83. 84.
    Rabinovici R (2003) Platelet activating factor inhibition in sepsis: the end? Crit Care Med 31: 1861–2PubMedGoogle Scholar
  84. 85.
    Natanson C, Esposito CJ, Banks SM (1998) The sirens songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 26: 1927–31PubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2005

Authors and Affiliations

  • I. Boyadjiev
  • F. Garnier
  • C. Martin

There are no affiliations available

Personalised recommendations